TY - JOUR
T1 - Age-related Changes in Bone Marrow Mesenchymal Stromal Cells
T2 - A Potential Impact on Osteoporosis and Osteoarthritis Development
AU - Ganguly, Payal
AU - El-Jawhari, Jehan J.
AU - Giannoudis, Peter V.
AU - Burska, Agata N.
AU - Ponchel, Frederique
AU - Jones, Elena A.
N1 - Funding Information:
The author(s) disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: Payal Ganguly is a recipient of PhD scholarship from Leeds Institute of Rheumatic and Musculoskeletal Medicine. Jehan J. El-Jawhari is supported by Arbeitsgemeinschaft für Osteosynthesefragen (AO) foundation grant. Agata N. Burska’s source of funding is Innovative Medicines Initiative (IMI)-funded project BeTheCure, 115142-2.
Publisher Copyright:
© 2017, © The Author(s) 2017.
PY - 2017/9/1
Y1 - 2017/9/1
N2 - Aging at the cellular level is a complex process resulting from accumulation of various damages leading to functional impairment and a reduced quality of life at the level of the organism. With a rise in the elderly population, the worldwide incidence of osteoporosis (OP) and osteoarthritis (OA) has increased in the past few decades. A decline in the number and “fitness” of mesenchymal stromal cells (MSCs) in the bone marrow (BM) niche has been suggested as one of the factors contributing to bone abnormalities in OP and OA. It is well recognized that MSCs in vitro acquire culture-induced aging features such as gradual telomere shortening, increased numbers of senescent cells, and reduced resistance to oxidative stress as a result of serial population doublings. In contrast, there is only limited evidence that human BM-MSCs “age” similarly in vivo. This review compares the various aspects of in vitro and in vivo MSC aging and suggests how our current knowledge on rejuvenating cultured MSCs could be applied to develop future strategies to target altered bone formation processes in OP and OA.
AB - Aging at the cellular level is a complex process resulting from accumulation of various damages leading to functional impairment and a reduced quality of life at the level of the organism. With a rise in the elderly population, the worldwide incidence of osteoporosis (OP) and osteoarthritis (OA) has increased in the past few decades. A decline in the number and “fitness” of mesenchymal stromal cells (MSCs) in the bone marrow (BM) niche has been suggested as one of the factors contributing to bone abnormalities in OP and OA. It is well recognized that MSCs in vitro acquire culture-induced aging features such as gradual telomere shortening, increased numbers of senescent cells, and reduced resistance to oxidative stress as a result of serial population doublings. In contrast, there is only limited evidence that human BM-MSCs “age” similarly in vivo. This review compares the various aspects of in vitro and in vivo MSC aging and suggests how our current knowledge on rejuvenating cultured MSCs could be applied to develop future strategies to target altered bone formation processes in OP and OA.
KW - aging
KW - bone marrow (BM)
KW - in vitro
KW - in vivo
KW - mesenchymal stromal cells (MSCs)
UR - http://www.scopus.com/inward/record.url?scp=85018362050&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85018362050&partnerID=8YFLogxK
U2 - 10.1177/0963689717721201
DO - 10.1177/0963689717721201
M3 - Review article
C2 - 29113463
AN - SCOPUS:85018362050
SN - 0963-6897
VL - 26
SP - 1520
EP - 1529
JO - Cell Transplantation
JF - Cell Transplantation
IS - 9
ER -